162 related articles for article (PubMed ID: 32092370)
1. Nasal administration of nanoencapsulated geraniol/ursodeoxycholic acid conjugate: Towards a new approach for the management of Parkinson's disease.
de Oliveira Junior ER; Truzzi E; Ferraro L; Fogagnolo M; Pavan B; Beggiato S; Rustichelli C; Maretti E; Lima EM; Leo E; Dalpiaz A
J Control Release; 2020 May; 321():540-552. PubMed ID: 32092370
[TBL] [Abstract][Full Text] [Related]
2. Nasal biocompatible powder of Geraniol oil complexed with cyclodextrins for neurodegenerative diseases: physicochemical characterization and in vivo evidences of nose to brain delivery.
Truzzi E; Rustichelli C; de Oliveira Junior ER; Ferraro L; Maretti E; Graziani D; Botti G; Beggiato S; Iannuccelli V; Lima EM; Dalpiaz A; Leo E
J Control Release; 2021 Jul; 335():191-202. PubMed ID: 34019946
[TBL] [Abstract][Full Text] [Related]
3. Brain uptake of a Zidovudine prodrug after nasal administration of solid lipid microparticles.
Dalpiaz A; Ferraro L; Perrone D; Leo E; Iannuccelli V; Pavan B; Paganetto G; Beggiato S; Scalia S
Mol Pharm; 2014 May; 11(5):1550-61. PubMed ID: 24717116
[TBL] [Abstract][Full Text] [Related]
4. Nasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuaries.
Dalpiaz A; Fogagnolo M; Ferraro L; Capuzzo A; Pavan B; Rassu G; Salis A; Giunchedi P; Gavini E
Antiviral Res; 2015 Nov; 123():146-57. PubMed ID: 26427553
[TBL] [Abstract][Full Text] [Related]
5. Characterization and Hydrolysis Studies of a Prodrug Obtained as Ester Conjugate of Geraniol and Ferulic Acid by Enzymatic Way.
Lerin LA; Botti G; Dalpiaz A; Bianchi A; Ferraro L; Chaibi C; Zappaterra F; Meola D; Giovannini PP; Pavan B
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892454
[TBL] [Abstract][Full Text] [Related]
6. Bile salt-coating modulates the macrophage uptake of nanocores constituted by a zidovudine prodrug and enhances its nose-to-brain delivery.
Dalpiaz A; Fogagnolo M; Ferraro L; Beggiato S; Hanuskova M; Maretti E; Sacchetti F; Leo E; Pavan B
Eur J Pharm Biopharm; 2019 Nov; 144():91-100. PubMed ID: 31521715
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease-A Pilot Study.
Sathe AG; Tuite P; Chen C; Ma Y; Chen W; Cloyd J; Low WC; Steer CJ; Lee BY; Zhu XH; Coles LD
J Clin Pharmacol; 2020 Jun; 60(6):744-750. PubMed ID: 32052462
[TBL] [Abstract][Full Text] [Related]
8. Dimeric ferulic acid conjugate as a prodrug for brain targeting after nasal administration of loaded solid lipid microparticles.
Botti G; Bianchi A; Dalpiaz A; Tedeschi P; Albanese V; Sorrenti M; Catenacci L; Bonferoni MC; Beggiato S; Pavan B
Expert Opin Drug Deliv; 2023; 20(11):1657-1679. PubMed ID: 38014509
[TBL] [Abstract][Full Text] [Related]
9. [Basic studies on the utility of ursodeoxycholic acid derivatives for clinical medicine].
Konishi T
Yakugaku Zasshi; 2000 Jan; 120(1):1-15. PubMed ID: 10655778
[TBL] [Abstract][Full Text] [Related]
10. Biopharmaceutical Potential of Selegiline Loaded Chitosan Nanoparticles in the Management of Parkinson's Disease.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Curr Drug Discov Technol; 2019; 16(4):417-425. PubMed ID: 29669501
[TBL] [Abstract][Full Text] [Related]
11. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting.
Jafarieh O; Md S; Ali M; Baboota S; Sahni JK; Kumari B; Bhatnagar A; Ali J
Drug Dev Ind Pharm; 2015; 41(10):1674-81. PubMed ID: 25496439
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of PLGA nanoparticles as delivery systems of a prodrug of zidovudine obtained by its conjugation with ursodeoxycholic acid.
Dalpiaz A; Contado C; Mari L; Perrone D; Pavan B; Paganetto G; Hanuskovà M; Vighi E; Leo E
Drug Deliv; 2014 May; 21(3):221-32. PubMed ID: 24134683
[TBL] [Abstract][Full Text] [Related]
13. Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review.
Kulkarni AD; Vanjari YH; Sancheti KH; Belgamwar VS; Surana SJ; Pardeshi CV
J Drug Target; 2015; 23(9):775-88. PubMed ID: 25758751
[TBL] [Abstract][Full Text] [Related]
14. Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: application of factorial design approach.
Pardeshi CV; Rajput PV; Belgamwar VS; Tekade AR; Surana SJ
Drug Deliv; 2013; 20(1):47-56. PubMed ID: 23311653
[TBL] [Abstract][Full Text] [Related]
15. Results of a phase I multiple-dose clinical study of ursodeoxycholic Acid.
Hess LM; Krutzsch MF; Guillen J; Chow HH; Einspahr J; Batta AK; Salen G; Reid ME; Earnest DL; Alberts DS
Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):861-7. PubMed ID: 15159320
[TBL] [Abstract][Full Text] [Related]
16. Intranasal delivery of mucoadhesive nanocarriers: a viable option for Parkinson's disease treatment?
Rehman S; Nabi B; Zafar A; Baboota S; Ali J
Expert Opin Drug Deliv; 2019 Dec; 16(12):1355-1366. PubMed ID: 31663382
[No Abstract] [Full Text] [Related]
17. Ursodeoxycholic acid complexation with 2-hydroxypropyl-beta-cyclodextrin increases ursodeoxycholic acid biliary excretion after single oral administration in rats.
Ventura P; Panini R; Montosi G; Garuti C; Vandelli M; Brunetti G; Tauschel H; Pietrangelo A; Salvioli G
Pharmacology; 2001 Feb; 62(2):107-12. PubMed ID: 11174081
[TBL] [Abstract][Full Text] [Related]
18. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations.
Tsai MJ; Huang YB; Wu PC; Fu YS; Kao YR; Fang JY; Tsai YH
J Pharm Sci; 2011 Feb; 100(2):547-57. PubMed ID: 20740670
[TBL] [Abstract][Full Text] [Related]
19. Intranasal nanotherapeutics for brain targeting and clinical studies in Parkinson's disease.
Saha P; Kathuria H; Pandey MM
J Control Release; 2023 Jun; 358():293-318. PubMed ID: 37061193
[TBL] [Abstract][Full Text] [Related]
20. Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer's disease.
Muntimadugu E; Dhommati R; Jain A; Challa VG; Shaheen M; Khan W
Eur J Pharm Sci; 2016 Sep; 92():224-34. PubMed ID: 27185298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
